712 related articles for article (PubMed ID: 30717771)
1. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2
Hu M; Xu C; Yang C; Zuo H; Chen C; Zhang D; Shi G; Wang W; Shi J; Zhang T
J Exp Clin Cancer Res; 2019 Feb; 38(1):49. PubMed ID: 30717771
[TBL] [Abstract][Full Text] [Related]
2. Metformin exerts multitarget antileukemia activity in JAK2
Machado-Neto JA; Fenerich BA; Scopim-Ribeiro R; Eide CA; Coelho-Silva JL; Dechandt CRP; Fernandes JC; Rodrigues Alves APN; Scheucher PS; Simões BP; Alberici LC; de Figueiredo Pontes LL; Tognon CE; Druker BJ; Rego EM; Traina F
Cell Death Dis; 2018 Feb; 9(3):311. PubMed ID: 29472557
[TBL] [Abstract][Full Text] [Related]
3. NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2
Fenerich BA; Fernandes JC; Rodrigues Alves APN; Coelho-Silva JL; Scopim-Ribeiro R; Scheucher PS; Eide CA; Tognon CE; Druker BJ; Rego EM; Machado-Neto JA; Traina F
Signal Transduct Target Ther; 2020 Jan; 5(1):5. PubMed ID: 32296029
[TBL] [Abstract][Full Text] [Related]
4. HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in polycythemia vera.
Menier C; Guillard C; Cassinat B; Carosella ED; Rouas-Freiss N
Leukemia; 2008 Mar; 22(3):578-84. PubMed ID: 18059484
[TBL] [Abstract][Full Text] [Related]
5. The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation.
Manshouri T; Quintás-Cardama A; Nussenzveig RH; Gaikwad A; Estrov Z; Prchal J; Cortes JE; Kantarjian HM; Verstovsek S
Cancer Sci; 2008 Jun; 99(6):1265-73. PubMed ID: 18482053
[TBL] [Abstract][Full Text] [Related]
6. Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm.
Pomicter AD; Eiring AM; Senina AV; Zabriskie MS; Marvin JE; Prchal JT; O'Hare T; Deininger MW
Exp Hematol; 2015 Jul; 43(7):537-45.e1-11. PubMed ID: 25912019
[TBL] [Abstract][Full Text] [Related]
7. WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation.
Verstovsek S; Manshouri T; Quintás-Cardama A; Harris D; Cortes J; Giles FJ; Kantarjian H; Priebe W; Estrov Z
Clin Cancer Res; 2008 Feb; 14(3):788-96. PubMed ID: 18245540
[TBL] [Abstract][Full Text] [Related]
8. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
[TBL] [Abstract][Full Text] [Related]
9. Ectopic PD-L1 expression in JAK2 (V617F) myeloproliferative neoplasm patients is mediated via increased activation of STAT3 and STAT5.
Guru SA; Sumi MP; Mir R; Waza AA; Bhat MA; Zuberi M; Lali P; Saxena A
Hum Cell; 2020 Oct; 33(4):1099-1111. PubMed ID: 32430672
[TBL] [Abstract][Full Text] [Related]
10. Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor.
Quintás-Cardama A; Manshouri T; Estrov Z; Harris D; Zhang Y; Gaikwad A; Kantarjian HM; Verstovsek S
Invest New Drugs; 2011 Oct; 29(5):818-26. PubMed ID: 20372971
[TBL] [Abstract][Full Text] [Related]
11. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.
Quintás-Cardama A; Vaddi K; Liu P; Manshouri T; Li J; Scherle PA; Caulder E; Wen X; Li Y; Waeltz P; Rupar M; Burn T; Lo Y; Kelley J; Covington M; Shepard S; Rodgers JD; Haley P; Kantarjian H; Fridman JS; Verstovsek S
Blood; 2010 Apr; 115(15):3109-17. PubMed ID: 20130243
[TBL] [Abstract][Full Text] [Related]
12. Dnmt3a is downregulated by Stat5a and mediates G0/G1 arrest by suppressing the miR-17-5p/Cdkn1a axis in Jak2
Zhou J; Guo C; Wu H; Li B; Zhou LL; Liang AB; Fu JF
BMC Cancer; 2021 Nov; 21(1):1213. PubMed ID: 34773997
[TBL] [Abstract][Full Text] [Related]
13. Three Tyrosine Residues in the Erythropoietin Receptor Are Essential for Janus Kinase 2 V617F Mutant-induced Tumorigenesis.
Ueda F; Tago K; Tamura H; Funakoshi-Tago M
J Biol Chem; 2017 Feb; 292(5):1826-1846. PubMed ID: 27998978
[TBL] [Abstract][Full Text] [Related]
14. Structure-function correlation of G6, a novel small molecule inhibitor of Jak2: indispensability of the stilbenoid core.
Majumder A; Govindasamy L; Magis A; Kiss R; Polgár T; Baskin R; Allan RW; Agbandje-McKenna M; Reuther GW; Keseru GM; Bisht KS; Sayeski PP
J Biol Chem; 2010 Oct; 285(41):31399-407. PubMed ID: 20667821
[TBL] [Abstract][Full Text] [Related]
15. mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.
Bogani C; Bartalucci N; Martinelli S; Tozzi L; Guglielmelli P; Bosi A; Vannucchi AM;
PLoS One; 2013; 8(1):e54826. PubMed ID: 23382981
[TBL] [Abstract][Full Text] [Related]
16. Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells.
Fiskus W; Verstovsek S; Manshouri T; Smith JE; Peth K; Abhyankar S; McGuirk J; Bhalla KN
Mol Cancer Ther; 2013 May; 12(5):577-88. PubMed ID: 23445613
[TBL] [Abstract][Full Text] [Related]
17. Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805.
Baffert F; Régnier CH; De Pover A; Pissot-Soldermann C; Tavares GA; Blasco F; Brueggen J; Chène P; Drueckes P; Erdmann D; Furet P; Gerspacher M; Lang M; Ledieu D; Nolan L; Ruetz S; Trappe J; Vangrevelinghe E; Wartmann M; Wyder L; Hofmann F; Radimerski T
Mol Cancer Ther; 2010 Jul; 9(7):1945-55. PubMed ID: 20587663
[TBL] [Abstract][Full Text] [Related]
18. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.
Pardanani A; Hood J; Lasho T; Levine RL; Martin MB; Noronha G; Finke C; Mak CC; Mesa R; Zhu H; Soll R; Gilliland DG; Tefferi A
Leukemia; 2007 Aug; 21(8):1658-68. PubMed ID: 17541402
[TBL] [Abstract][Full Text] [Related]
19. Proliferation and survival signaling from both Jak2-V617F and Lyn involving GSK3 and mTOR/p70S6K/4EBP1 in PVTL-1 cell line newly established from acute myeloid leukemia transformed from polycythemia vera.
Nagao T; Kurosu T; Umezawa Y; Nogami A; Oshikawa G; Tohda S; Yamamoto M; Miura O
PLoS One; 2014; 9(1):e84746. PubMed ID: 24404189
[TBL] [Abstract][Full Text] [Related]
20. HDAC8 overexpression in mesenchymal stromal cells from JAK2+ myeloproliferative neoplasms: a new therapeutic target?
Ramos TL; Sánchez-Abarca LI; Redondo A; Hernández-Hernández Á; Almeida AM; Puig N; Rodríguez C; Ortega R; Preciado S; Rico A; Muntión S; Porras JRG; Del Cañizo C; Sánchez-Guijo F
Oncotarget; 2017 Apr; 8(17):28187-28202. PubMed ID: 28390197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]